Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

CytoDyn gets $25M in convertible debt deal to fund license applications, coronavirus trials for leronlimab

% of readers think this story is Fact. Add your two cents.

CytoDyn Inc (OTCQB:CYDY) announced Wednesday that it has gone through a second non-dilutive convertible debt offering with an institutional investor, delivering $25 million of immediately available capital for the company’s license applications and coronavirus (COVID-19) trials. 

The note has a two-year maturity, bears interest at the rate of 10% annually and is secured by all assets of the company, excluding its intellectual property. The note may be converted into shares of common stock at a price of $10.00 per share. 

The company believes the influx of cash will help grease the runway to complete the biologics licence application (BLA) process for its drug leronlimab around the world. 

READ: CytoDyn wins nod from UK’s MHRA to file BLA for leronlimab as a once a week injection for a HIV combo therapy

“We are very pleased with the institution’s demonstration of confidence and their understanding of leronlimab’s positioning on its regulatory trajectory,” CEO Nader Pourhassan said in a statement. “This infusion of capital will enable us to accelerate efforts to file BLAs in Canada and the UK for leronlimab as a combination therapy for HIV patients with one dose (one 350 mg subcutaneous injection) per week.”

Leronlimab is also being evaluated as a possible treatment for the coronavirus.

“We continue to expedite enrollment in CD12 (currently at 260 patients), in addition to now accelerating a COVID-19 trial for long-hauler patients, who have no alternative therapy and are rapidly emerging as a widespread health concern,” Pourhassan said. “We are well-positioned to supply $2 billion worth of leronlimab to treat COVID-19, if emergency use authorization is approved in the next 2-4 months based on anticipated successful CD12 results.”

Leronlimab works by mitigating what is known as the cytokine storm, a hyperactive immune response that can cause inflammation, fatigue and, in severe cases, organ failure.

In addition to its potential as a treatment for the coronavirus, leronlimab has previously been granted Fast Track designation by the Food and Drug Administration as a combination therapy with HAART for HIV-infected patients and as a treatment for metastatic triple-negative breast cancer.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Load more ...




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.